CHEMOCENTRYX
ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
CHEMOCENTRYX
Industry:
Biotechnology Health Care Medical Device
Founded:
1997-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.chemocentryx.com
Total Employee:
101+
Status:
Active
Contact:
+1.650.210.2900
Email Addresses:
[email protected]
Total Funding:
634.34 M USD
Technology used in webpage:
SPF SSL By Default Mobile Non Scaleable Content Amazon IPv6 Google Maps ReCAPTCHA Microsoft Azure DNS Google Maps API Apple Mobile Web App Capable
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Myomo
Myomo develops devices with myoelectric prosthetic technology to restore the mobility of individuals with muscle weakness.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - ChemoCentryx
Alta Partners
Alta Partners investment in Series E - ChemoCentryx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series E - ChemoCentryx
Glaxo Group
Glaxo Group investment in Series E - ChemoCentryx
HealthCap
HealthCap investment in Series E - ChemoCentryx
Glaxo Group
Glaxo Group investment in Series D - ChemoCentryx
OrbiMed
OrbiMed investment in Series D - ChemoCentryx
Gimv
Gimv investment in Series D - ChemoCentryx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - ChemoCentryx
Alta Partners
Alta Partners investment in Series D - ChemoCentryx
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-11 | ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer |
Official Site Inspections
http://www.chemocentryx.com Semrush global rank: 4.64 M Semrush visits lastest month: 2.14 K
- Host name: cloudproxy10158.sucuri.net
- IP address: 192.124.249.158
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ChemoCentryx" on Search Engine
ChemoCentryx - Crunchbase Company Profile & Funding
About. ChemoCentryx is a biopharmaceutical company that develops medications for inflammatory and autoimmune diseases and cancer. Acquired by. Amgen. San Carlos, California, United States. 101-250. Post-IPO Equity. Public. www.chemocentryx.com. …See details»
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 …
Aug 4, 2022 THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the …See details»
AMGEN SUCCESSFULLY COMPLETES ACQUISITION …
Oct 20, 2022 ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies.See details»
ChemoCentryx Company Profile - Office Locations, …
Mar 3, 2022 Company Summary. ChemoCentryx is a biopharmaceutical company commercializing and developing medications for inflammatory and autoimmune diseases and cancer. It focuses on orphan and rare diseases, chronic kidney disease, immuno-oncology, and other inflammatory diseases.See details»
Amgen continues buying spree with $3.7B ChemoCentryx deal
Aug 4, 2022 (Amgen) Facing one of the biopharma industry’s steepest patent cliffs for the decade, Amgen has been on a shopping spree. The latest purchase? A $3.7 billion deal to acquire ChemoCentryx. The...See details»
Amgen bets on ChemoCentryx's rare disease drug in $3.7
Aug 4, 2022 Amgen Inc on Thursday agreed to buy ChemoCentryx Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders and beat quarterly revenue estimates on demand...See details»
Amgen to Acquire ChemoCentryx for $3.7B, Bolstering …
Aug 5, 2022 Amgen has agreed to acquire ChemoCentryx for approximately $3.7 billion, the companies said today, in a deal that expands the buyer’s autoimmune portfolio with an approved drug and two clinical...See details»
Amgen Will Acquire Chemocentryx in $4 Billion Deal
On Aug. 4, 2022, Amgen announced a definitive agreement to acquire ChemoCentryx, a biopharmaceutical company specializing in therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, for $52 per share in cash, which represents an enterprise value of approximately $3.7 billion.See details»
Amgen to buy ChemoCentryx for $4 billion cash - San …
Aug 4, 2022 Like Five Prime, ChemoCentryx probably will be folded into the 22,000-person Amgen organization, with the ChemoCentryx drug portfolio moving into the hands of Amgen research and development...See details»
Amgen to acquire ChemoCentryx for $4 billion - STAT
Aug 4, 2022 Biotech. Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder. By Adam Feuerstein. Reprints. Mark J. Terrill/AP. A mgen said Thursday that it will...See details»
ChemoCentryx Announces FDA Approval of …
SAN CARLOS, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an...See details»
Amgen bets almost $4B on a biotech and its inflammation drugs
Aug 4, 2022 Amgen plans to acquire a fellow Californian biotechnology company, ChemoCentryx, for $3.7 billion in a deal meant to deepen its pool of medicines targeting inflammation and the kidneys. The companies expect their deal, announced Thursday, to close sometime between October and December.See details»
ChemoCentryx - Funding, Financials, Valuation & Investors
ChemoCentryx is a biopharmaceutical company that develops medications for inflammatory and autoimmune diseases and cancer.See details»
ChemoCentryx scores first FDA approval in 24-year history, and …
Oct 8, 2021 Pharma. ChemoCentryx scores first FDA approval in 24-year history, and CEO Schall sees a blockbuster in the making. By Kevin Dunleavy Oct 8, 2021 10:08am. drug approval ChemoCentryx Tavneos...See details»
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF …
Oct 20, 2022 ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and...See details»
ChemoCentryx Announces Changes to its Board of Directors
May 31, 2022 ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and...See details»
ChemoCentryx Announces Changes to its Board of Directors
SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced changes to the composition of its Board of Directors. David E. Wheadon, M.D., has been...See details»
Vifor Pharma Group increases equity investments in ChemoCentryx*
Sep 18, 2018 ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases, and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orallyadministered therapies.See details»
ChemoCentryx Inc | Reuters
The latest international ChemoCentryx Inc news and views from Reuters - one of the world's largest news agenciesSee details»
ChemoCentryx | LinkedIn
About us. ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company founded in 1997 commercializing and developing new medications for inflammatory and autoimmune diseases and cancer....See details»